Maddocks

A court has directed a senior barrister acting in a $650 million lawsuit against Mercedes-Benz to “tear up” a letter his instructing solicitors sent concerning the judge’s ownership of a Mercedes vehicle, and said he was “surprised” the counsel signed off on it.

A judge has declined to pass on a senior barrister’s $18,000 cancellation fee as part of an adverse costs order for a vacated trial, noting that such fees are not standard or common practice.

Mercedes can’t access communications between Australia’s peak body for car dealers and a Labor senator to use in its defence of a $650 million lawsuit over its decision to move to a fixed-price agency model.

Officials at the Mercedes-Benz Australia head office referred to car dealers as “baby piglets” in internal communications and threatened and bullied the retailers, a trial court has been told in a $650 million lawsuit over the car maker’s decision to move to a fixed-price agency model.

Mercedes Benz Australia will produce 10,000 pages of documentary evidence alongside material from CEO Florian Seidler, in its fight against a $650 million lawsuit brought by Australian dealers over the car maker’s decision to move to a fixed-price agency model.

A former Deloitte director accused of embezzling $3.1 million to fund lavish purchases, including an extensive art collection, has been referred to police and suspended by an association for Australian restructuring professionals.

A former Deloitte director accused of embezzling $3.1 million has agreed to court orders that he repay the money and hand over title to all assets — including almost 100 works of art — purchased with the alleged misappropriated funds.

Australian Mercedes-Benz dealers behind a $650 million lawsuit over the car maker’s decision to move to a fixed-price agency model have lost a bid for an “ambitious number” of dealers to view “super confidential” documents from the company’s head office in Germany.

The Full Federal Court won’t give Swiss pharmaceuticals giant Novartis the chance to appeal a ruling that threw out three of its four experts in a patent case against generic drug maker Pharmacor.

Novartis wants to appeal a ruling in its dispute with generic drug maker Pharmacor over patents for its multiple sclerosis drug Gilenya that tossed three of its four experts out of an upcoming so-called hot tub.